Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells consist of a defined proportion of CD4 and CD8 positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domain and a truncated human epidermal growth factor receptor (EGFRt), which has potential cytotoxic activity against CD19-expressing tumor cells (NCI Thesaurus).|
|Iomab-B||I 131 MOAB BC8|131-I Apamistamab|Iodine I 131 Apamistamab||Iomab-B (131-I Apamistamab) comprises an antibody targeting CD45 conjugated to iodine 131 (I-131), which delivers I-131 to CD45-expressing cells, potentially resulting in increased death of CD45-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04512716||Phase I||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B||Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma||Not yet recruiting|